E3 ligase MG53 suppresses tumor growth by degrading cyclin D1

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Aberrant cyclin D1 expression is a hallmark of many cancers, driving cell cycle progression and contributing to treatment resistance.
• Dysregulation of cyclin D1 ubiquitination and degradation is implicated in cancer pathogenesis and therapeutic failure, particularly with CDK4/6 inhibitors.

Purpose of the Study:

• To investigate the role of MG53 in regulating cyclin D1 stability and its implications in colorectal and gastric cancers.
• To elucidate the mechanism by which MG53 influences cell cycle progression and tumor growth.

Main Methods:

• Analysis of MG53 and cyclin D1 expression in patient tumor tissues and normal adjacent tissues.
• In vitro and in vivo experiments assessing the impact of MG53 modulation on cell cycle, proliferation, and tumor growth.
• Mechanistic studies involving ubiquitination assays to determine MG53's role in cyclin D1 degradation.

Main Results:

• MG53 is significantly downregulated in over 80% of colorectal and gastric tumors, inversely correlated with cyclin D1 levels and patient survival.
• MG53 directly catalyzes K48-linked ubiquitination of cyclin D1, leading to its degradation and G1 cell cycle arrest.
• Overexpression of MG53 suppresses cancer cell proliferation and tumor growth in preclinical models, while MG53 deficiency accelerates cancer progression.

Conclusions:

• MG53 functions as a tumor suppressor by promoting cyclin D1 degradation, thereby inhibiting cell cycle progression.
• MG53's role in regulating cyclin D1 turnover presents a novel therapeutic strategy for cancers characterized by dysregulated cyclin D1.
• Targeting MG53 could offer a new avenue for treating malignancies resistant to current therapies.